SCHEMBL20578205

SCHEMBL20578205

O=C(NS(=O)(=O)C1CC1)c1cc(Cl)c(OC[C@H]2CCCN2c2ccc(C(F)(F)F)nc2)cc1F

nearest known ligand 0.55

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 20/20 0.55
▸ SCN5A Q14524 2/20 0.49
▸ SCN4A P35499 1/20 0.46
▸ SCN2B O60939 1/20 0.46
▸ SCN1B Q07699 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20578206 1.00 SCN9A (0.55) SCN9ASCN5ASCN4ASCN2BSCN1B
SCHEMBL20668562 0.90 SCN9A (0.58) SCN9ASCN5ASCN4A
SCHEMBL28416267 0.90 SCN9A (0.58) SCN9ASCN5ASCN4A
SCHEMBL18013377 0.87 SCN9A (0.42) SCN9A
SCHEMBL20668692 0.86 FPR1 (0.46) SCN9A
SCHEMBL20578064 0.85 SCN9A (0.55) SCN9ASCN5ASCN4A
SCHEMBL20578062 0.85 SCN9A (0.55) SCN9ASCN5ASCN4A
SCHEMBL18013219 0.81 SCN9A (0.61) SCN9ASCN5ASCN4A
SCHEMBL28388959 0.80 SCN9A (0.56) SCN9A
SCHEMBL28388958 0.80 SCN9A (0.56) SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10815197-B2 N-sulfonyl benzamides as voltage-gated sodium channel inhibitors SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2020-10-27 — — US disclosed
US-10815197-B2 N-sulfonyl benzamides as voltage-gated sodium channel inhibitors SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2020-10-27 — — US disclosed
CN-108430969-B Heterocyclic substituted N-sulfonyl benzamide derivative, preparation method and medical application thereof 上海海雁医药科技有限公司 2020-06-02 — — CN disclosed
US-20190023654-A1 N-SULFONYL BENZAMIDE DERIVATIVE WITH HETEROCYCLIC SUBSTITUENT, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) 2019-01-24 — — US disclosed
US-20190023654-A1 N-SULFONYL BENZAMIDE DERIVATIVE WITH HETEROCYCLIC SUBSTITUENT, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) 2019-01-24 — — US disclosed
EP-3412653-A1 N-SULFONYL BENZAMIDE DERIVATIVE WITH HETEROCYCLIC SUBSTITUENT, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) 2018-12-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815197-B2 N-sulfonyl benzamides as voltage-gated sodium channel inhibitors SCN11A, SCN8A, NHERF1 SCN9A 73/4885SCN5A 9/4885SCN4A 24/4885
US-20190023654-A1 N-SULFONYL BENZAMIDE DERIVATIVE WITH HETEROCYCLIC SUBSTITUENT, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF SLC5A11, SLC6A11, SLC5A1 SCN9A 1223/4885SCN5A 199/4885SCN4A 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback